David-Alexandre Gros, MD, MBA

D.A. Gros has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. Most recently, D.A. was President, Chief Operating Officer and acting Chief Financial Officer of Neurocrine Biosciences.  During his tenure, Neurocrine received FDA approval for and launched Ingrezza®, and completed a $517.5 million financing.

Prior to Neurocrine, D.A. served as Senior Vice President, Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals where his responsibilities included strategy, finance, business development, communications, investor relations, and shared services.  Prior to Alnylam, as Executive Vice President and Chief Strategy Officer at Sanofi, D.A.’s responsibilities included corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments, including the corporate venture fund which he re-launched.  Before Sanofi, D.A. held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company.

D.A. holds an M.D. from the Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School, and an A.B. from Dartmouth College.